Bharat Biotech, promoted by a group of medical and healthcare professionals, entered the field of Biotechnology to solve some of regional health problems. Its goal is to bring international technology expertise and tools to solve domestic issues at an affordable cost that can reach even rural population. Bharat Biotech is also seeking viable alternative remedies for infectious diseases endemic to the Asian region.

Revac-8, the maiden product was launched in 1998 and product has been well accepted in the market. Doctors have accepted the product at par with multinational brands. Initially, the production capacity was aimed at 8 million doses and presently the production capacity has been increased to more than 100 million doses per annum, perhaps the largest in Asia and Pacific region.

To this effect, Ministry of Industries, Government of India issued license to manufacture 106 million doses per annum.

Bharat Biotech is setting up an R&D center in the campus of Indian Institute of Science, Bangalore.

Bharat Biotech is interested in total healthcare of the people. BBIL is mainly focussing on regional specific diseases and its control. For example, Malaria is very epidemic in all state of this country. Eradicalon of this disease is very difficult and BBIL would like to focus on malarial vaccine research.

Similarly, many children are dying due to diarrhea in India particularly in rural areas and BBIL is workign with the Indian and US institutions to develop a cost effective diarrheal vaccine. Similarly, BBIL would like to build a research-oriented knowledge base for known and unknown infectious diseases.